Defymed

Defymed is a worldwide leader in the development of innovative implantable medical devices that change the paradigm of therapeutics' administration. Defymed's innovations  were developed to limit adverse events related to current standard of care based on site specific delivery of therapeutics. Our solutions aim for a precise administration of drugs, in a physiologic site, in order to improve disease's management and patients' quality of life. Up to date, two first in class technologies were developed by Defymed: MailPan®, a physiologic cell encapsulation device, and ExOlin®, a targeted drug delivery device. 

Defymed owns an exclusive technology and know-how which position its medical devices as a platform to meet several therapeutic applications, among which type 1 diabetes, hemophilia and cancer (non exhaustive list). Defymed is certified ISO13485:2016.

Defymed relies also on a strong and unique worldwide network gathering experts from the cell therapy and drug delivery fields. Defymed has been rewarded several times in Europe and in the USA, for its unique approaches to reinvent patients' journey.